Analytical Data
-
基因名
tPA
- Application
-
别名
tPA；Tissue-type plasminogen activator
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P00750
-
表达区间
36-562aa
-
氨基酸序列
SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKS CSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISY RGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRD SKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGAS CLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRR LTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRS PGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQ KFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPAD LQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRT VTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGL GCGQKDVPGVYTKVTNYLDWIRDNMRPVDHHHHHH
-
分子量
61 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Tissue Plasminogen Activator (tPA) is a crucial recombinant protein that plays a significant role in the medical management of thrombotic conditions, particularly in the treatment of acute ischemic stroke. Originally isolated from human endothelial cells, tPA functions as a serine protease that catalyzes the conversion of plasminogen to plasmin, leading to the dissolution of fibrin clots. Its efficacy in restoring blood flow and reducing neuronal damage in stroke patients has made it a standard therapeutic agent since its approval in the early 1990s. Research in the field has focused on optimizing the pharmacokinetics and safety profile of tPA, as well as exploring its potential applications in other thrombotic disorders, such as myocardial infarction and pulmonary embolism. Additionally, scientists are investigating modifications to enhance its specificity and reduce the risk of hemorrhagic complications, a significant concern associated with its use. Advances in biotechnology have facilitated the production of recombinant tPA, allowing for greater availability and consistency in treatment. Ongoing studies aim to better understand the molecular mechanisms of tPA action, leading to improved therapeutic strategies and potentially identifying novel indications for its use. Overall, the research surrounding tPA continues to evolve, reflecting its importance in the realm of cardiovascular and cerebrovascular medicine.
